Recent 8-K filings for ZVRA

• May 6, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  Zevra Q1 2026 net revenue $36.2M (+78% YoY); net income $37.9M; cash $236.8M after debt repayment

  MIPLYFFA net revenue $24.6M; total net revenue $36.2M vs $20.4M in Q1 2025.

• March 16, 2026, 7:59 PM ET M&A materiality 0.75 positive item 1.01item 1.02item 7.01item 9.01 ◈ Material Agreements ×2

  Zevra sells SDX portfolio to Commave for $50M, settles lawsuit, repays $63M debt

  Total purchase price $50M; $25M at signing, $20M within 10 business days, $5M after records delivery.

• March 9, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 5.02item 9.01

  Zevra reports Q4 net revenue $34.1M, net income $12.2M; appoints Justin Renz as CFO

  Q4 2025 net revenue $34.1M (+31% QoQ); net income $12.2M ($0.19 diluted EPS) vs. $(35.7)M loss in Q4 2024.

• November 20, 2025, 6:59 PM ET leadership materiality 0.60 neutral item 5.02item 7.01item 9.01

  Zevra Therapeutics CFO R. LaDuane Clifton resigns effective Dec 31, 2025

  CFO Clifton to depart Dec 31, 2025 to pursue other professional opportunities.

• November 5, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Zevra Q3 net loss narrows to $0.5M; revenue jumps to $26.1M on MIPLYFFA sales

  Q3 net revenue $26.1M (vs $3.7M YoY), with MIPLYFFA contributing $22.4M.

• August 12, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Zevra Q2 net revenue $25.9M, net income $74.7M on PRV sale; adjusted net loss $3.2M

  Product net revenue $21.8M (MIPLYFFA $21.5M, OLPRUVA $0.3M) vs $4.4M total revenue in Q2 2024.

• May 13, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Zevra Q1 net revenue $20.4M, PRV sale nets $148M; net loss narrows to $3.1M

  Q1 2025 net revenue $20.4M (up from $3.4M YoY); MIPLYFFA contributed $17.1M, OLPRUVA $0.1M.

• April 7, 2025, 7:59 PM ET other material materiality 0.75 positive item 2.01item 2.02item 8.01item 9.01

  Zevra closes $150M sale of rare pediatric disease PRV, boosting cash to ~$217M

  Closed sale of Rare Pediatric Disease Priority Review Voucher for $150M gross proceeds on April 1, 2025.

• March 11, 2025, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01

  Zevra Therapeutics reports FY 2024 net loss of $105.5M; sells PRV for $150M, cash runway into 2029

  FY 2024 net revenue $23.6M (record Q4 product revenue $10.2M from MIPLYFFA); net loss ($105.5M) vs ($46.0M) in 2023.

• February 27, 2025, 6:59 PM ET other material materiality 0.80 positive item 1.01item 7.01item 9.01

  Zevra sells PRV for $150M cash; funds MIPLYFFA & OLPRUVA launches

  Gross proceeds of $150M, payable in cash at closing; expected within 30-45 days.

• December 6, 2024, 6:59 PM ET leadership materiality 0.80 neutral item 5.02item 7.01item 9.01

  Zevra Therapeutics Announces Departure of Chief Development Officer and Chief Scientific Officer

  Christal Mickle, Chief Development Officer and Co-Founder, notified of departure effective Dec. 6, 2024.

• November 22, 2024, 6:59 PM ET other material materiality 0.70 positive item 7.01item 8.01item 9.01

  Zevra launches MIPLYFFA for NPC; early adoption ahead of expectations

  MIPLYFFA (arimoclomol) commercially available at Zevra's specialty pharmacy; first FDA-approved NPC treatment.

• November 12, 2024, 6:59 PM ET earnings materiality 0.85 neutral item 2.02item 9.01

  Zevra Q3 net loss $33.2M; FDA approval of MIPLYFFA for NPC marks key milestone

  Net loss of $33.2M ($0.69 per share) vs. $10.4M loss in Q3 2023; revenue $3.7M from French EAP and AZSTARYS royalties.

• September 20, 2024, 7:59 PM ET regulatory materiality 0.90 positive item 7.01item 8.01item 9.01

  Zevra Therapeutics' MIPLYFFA receives FDA approval as first treatment for Niemann-Pick disease type C

  FDA approved MIPLYFFA (arimoclomol) for NPC in adult and pediatric patients 2 years+; first FDA-approved NPC treatment.

• August 13, 2024, 7:59 PM ET earnings materiality 0.85 neutral item 2.02item 9.01

  Zevra Q2 revenue falls to $4.4M, net loss $19.9M; FDA decision on arimoclomol by Sept 21

  Net revenue $4.4M vs $8.5M YoY; net loss $19.9M ($0.48/share) vs $2.6M ($0.08/share) in Q2 2023.

• August 9, 2024, 7:59 PM ET other material materiality 0.65 neutral item 8.01item 9.01

  Zevra Therapeutics prices $60M common stock offering at $6.50/share; net proceeds ~$56.1M

  9,230,770 shares sold at $6.50; underwriters have 30-day option for 1,384,615 additional shares.

• August 8, 2024, 7:59 PM ET earnings materiality 0.80 negative item 2.02

  Zevra Therapeutics Reports Preliminary Q2 2024 Revenue of $4.2-$4.6 Million, Net Loss Widens to $18.9-$19.8 Million

  Revenue for Q2 2024 expected between $4.2M and $4.6M, down from $8.47M in Q2 2023 which included a $5.0M milestone payment from AZSTARYS license.

• August 5, 2024, 7:59 PM ET regulatory materiality 0.75 positive item 7.01item 8.01item 9.01

  FDA panel votes 11-5 that Zevra's arimoclomol is effective for NPC; PDUFA date Sep 21

  FDA GeMDAC voted 11 yes, 5 no that data support arimoclomol as effective for Niemann-Pick disease type C.

• July 9, 2024, 7:59 PM ET regulatory materiality 0.70 neutral item 7.01item 8.01item 9.01

  Zevra announces FDA advisory committee meeting for arimoclomol on Aug 2, 2024

  FDA's Genetic Metabolic Diseases Advisory Committee (GeMDAC) will review arimoclomol NDA for Niemann-Pick disease type C.

• June 3, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Zevra reports positive Phase 2 trial results for KP1077 in idiopathic hypersomnia

  KP1077 well-tolerated at up to 320 mg/day; AEs similar to methylphenidate, mostly mild (insomnia, headache, anxiety).

• May 8, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Zevra Q1 net loss $16.6M; OLPRUVA launch with 4 patients, cash runway into 2026

  Net loss of $16.6M ($0.40 loss per share) compared to $13.2M loss in Q1 2023.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.75 · Most common event earnings

11 positive 3 negative 12 neutral

source · ZVRA on sec.gov